EGFR and adenocarcinoma: Interestingly, a recent retrospective study involving 67 patients indicated that transformed SCLCs respond more favorably to taxanes compared to de novo SCLCs but displayed resistance to checkpoint inhibitors, mirroring the behavior of typical EGFR-mutant adenocarcinomas [217].